NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

腫瘤領域的精密醫療的全球市場 (2020-2030年):各應用領域、生態系統類型、地區/主要國家

Global Oncology Precision Medicine Market: Focus on Application Area, Ecosystem Type, Country Data (15 Countries) - Analysis and Forecast, 2020-2030

出版商 BIS Research Inc. 商品編碼 976440
出版日期 內容資訊 英文 297 Pages
商品交期: 最快1-2個工作天內
價格
腫瘤領域的精密醫療的全球市場 (2020-2030年):各應用領域、生態系統類型、地區/主要國家 Global Oncology Precision Medicine Market: Focus on Application Area, Ecosystem Type, Country Data (15 Countries) - Analysis and Forecast, 2020-2030
出版日期: 2020年12月07日內容資訊: 英文 297 Pages
簡介

腫瘤的精密醫療的市場規模在預測期間內預計以11.21%的年複合成長率發展,從2019年的469億美元,成長到2030年1486億6000萬美元的規模。癌症的發病率、死亡率的上升,政府的積極推動,分子等級診斷、治療的一般人的意識高漲,分子診斷的進步,FDA的核準增加,對主要的醫療保健企業的R&D的焦點等要素促進該市場的成長。

本報告提供全球腫瘤領域的精密醫療的市場調查,市場定義和概要,癌症管理、治療的精密醫療的演進,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,法律上的要求與架構,專利趨勢,市場規模的變化、預測,用途、生態系統、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊彙整。

摘要整理

第1章 產品定義

第2章 調查範圍

第3章 調查手法

第4章 市場概要

  • 癌症管理、治療用精密醫療的演進
  • 腫瘤領域的精密醫療的應用

第5章 COVID-19的影響

第6章 產業分析

  • 法律上的要求、規定上架構
  • 專利情勢

第7章 市場動態

  • 概要
  • 市場成長的促進因素
  • 市場成長的阻礙因素
  • 市場機會

第8章 競爭情形

  • 主要策略、展開
  • 市場佔有率分析
  • 成長、佔有率分析:各企業

第9章 市場分析、預測:各用途

  • 乳癌
  • 肺癌症
  • 結腸直腸癌症
  • 前列腺癌症
  • 子宮頸癌症
  • 其他

第10章 市場分析、預測:各生態系統

  • 應用科學
    • 基因學
      • 藥理基因學
      • 其他
  • 精密診斷
    • 分子診斷(MDx)
    • 醫療影像處理
  • 數位健康、IT
    • 臨床決策支援系統(CDSS)
    • 巨量資料分析
    • IT基礎設施
    • 基因學資訊學
    • In Silico資訊學
    • 行動醫療
  • 精密治療
    • 臨床試驗
    • 細胞療法
    • 藥物研發、研究
    • 基因治療

第11章 市場分析、預測:各地區、主要國家

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他地區

第12章 企業簡介

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Almac Group Ltd.
  • ANGLE plc
  • ASURAGEN INC.
  • BGI Group
  • Bio-Rad Laboratories, Inc.
  • bioMerieux S.A.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • Illumina, Inc.
  • Konica Minolta, Inc.
  • Laboratory Corporation of America Holdings
  • MDx Health, Inc.
  • Myriad Genetics, Inc
  • Novartis AG
  • OPKO Health, Inc.
  • Pacific Biosciences of California, Inc.
  • Quest Diagnostics
  • QIAGEN N.V.*
  • Thermo Fisher Scientific Inc.
目錄
Product Code: BHP1015SA

"The Global Oncology Precision Medicine Market to Reach $148.66 Billion by 2030."

Market Report Coverage - Oncology Precision Medicine

Market Segmentation

  • By Application: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Other Applications
  • By Ecosystem: Applied Sciences, Precision Diagnostics, Digital Health and Information Technology, Precision Therapeutics
  • By Region: North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe
  • Asia-Pacific - China, Australia, Japan, India, and Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, and Rest-of-LATAM
  • Rest-of-the-World

Growth Drivers

  • Increasing Incidences of Cancer
  • Decreasing Trial and Error-Based Drug Prescription Through Pharmacogenomics
  • Rapid Technological Advancements
  • Increasing Usage of Predictive Biomarker for Diagnostics
  • Decreasing Cost of Genomic Sequencing

Market Challenges

  • Large Scale Data Integration, Analysis and Establishment of Secure Data Libraries
  • Inadequate Reimbursement Scenario for Precision Medicine
  • Regulatory Barriers in the Advancement of Precision Medicine
  • Lack of Expertise, Education and Awareness for Precision Medicine Implementation

Market Opportunities

  • Unprecedented Improvements in Disease Modelling via In Silico, In Vitro, and In Vivo Methods
  • Expansion into the Emerging Markets

Key Oncology Precision Medicine Companies Profiled

Abbott Laboratories, Agilent Technologies, Inc., Almac Group Ltd., ANGLE plc, Asuragen, Inc.,AstraZeneca PLC, Bristol Myers Squibb, bioMerieux SA., BGI Group, Bio-Rad Laboratories, Inc F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Gilead Sciences, Inc. Illumina, Inc, Konica Minolta, Inc., Laboratory Corporation of America Holdings, MDx Health, Inc., Myriad Genetics, Inc., Novartis AG, Opko Health,Inc., Pacific Biosciences of California, Inc.,Teva Pharmaceutical Industries Ltd., Thermofisher Scientific, QIAGEN, and Quest Diagnostics

Key Questions Answered in this Report:

  • What are the most common causes of cancer deaths globally?
  • What are the emerging technologies that can take over the current technologies for molecular diagnosis within the oncology precision medicine market?
  • What is the patent expiry scenario of the key companion diagnostics-based drugs within the market?
  • How are the key market players performing research investments in the respective market?
  • Who are the upcoming start-ups within the oncology precision medicine market and their funding scenario?
  • What are the key development strategies implemented by the key players to stand out in this market?
  • How have the strategic collaborations among the key players and academia, providing a push to product development within the oncology precision medicine market?
  • What are the regulations pertaining to the precision medicine in oncology among different regions and their impact over the respective market?
  • What are the initiatives implemented by different government bodies regulating the development and commercialization of oncology precision medicine products and associated platforms?
  • How has COVID-19 impacted the oncology precision medicine market?
  • How will the urgency of the pandemic influence the global oncology precision medicine market?
  • What are the leading companies dominating the global oncology precision medicine market?
  • What is the reimbursement scenario of the products offered in the global oncology precision medicine market?
  • Based on the application area, which global oncology precision medicine market application area is anticipated to witness a massive rise in demand in the forecast period?
  • How is each segment of the global oncology precision medicine market expected to grow during the forecast period, and what is the revenue expected to be generated by each of the segments by the end of 2030?
  • How is the global oncology precision medicine industry anticipated to evolve during the forecast period 2020-2030?
  • What are the leading trends and consumer preferences witnessed in the global oncology precision medicine market?

Market Overview

Precision medicine is a concept that collectively integrates the outcomes and the endeavors of research and healthcare. The ability to tailor the diagnostics and therapeutics offered to the patients is the key to precision medicine. The combination of biotechnology development, digitization of healthcare, and public investment led to the evolution of the personalization of disease-based therapies.

This evolution within precision medicine will profoundly impact the biopharmaceutical industry, and multiple players from biopharma to diagnostics companies with multiple functions such as research and development to commercial operations will witness a change.

The global oncology precision medicine market was valued at $46.90 billion in 2019, and it is expected to grow at an impressive double-digit rate of 11.21% and reach a value of $148.66 billion in 2030.

The existing oncology precision medicine market is favored by multiple factors, which include rising cancer incidences and death rates, several government initiatives, coupled up with the general population's growing awareness pertaining to molecular level diagnosis and treatment. Additionally, the increasing number of advancements in molecular diagnostics, increasing FDA approvals for such precision medicine-based oncology drugs, improving focus on research and development activities by key healthcare companies are also leading toward market expansion.

Within the research report, the market is segmented on the basis of application (breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, other applications), ecosystem type (applied sciences, precision diagnostics, digital health and information technology, precision therapeutics), and region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, and future opportunities to detail the scope and provide a 360-coverage of the domain.

Competitive Landscape

The oncology precision medicine market witnessed 78 collaborations and partnerships, four funding and investments, 45 product launches and enhancements, 22 regulatory and legal activities, 17 mergers and acquisitions, and six business expansions.

Major players within the oncology precision medicine market are: Abbott Laboratories, Agilent Technologies, Inc., Almac Group Ltd., ANGLE plc, Asuragen Inc., AstraZeneca PLC, Bristol Myers Squibb, bioMerieux SA., BGI Group, Bio-Rad Laboratories, Inc F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Gilead Sciences, Inc. Illumina, Inc, Konica Minolta, Inc., Laboratory Corporation of America Holdings, MDx Health, Inc., Myriad Genetics, Inc., Novartis AG, Opko Health,Inc., Pacific Biosciences of California, Inc.,Teva Pharmaceutical Industries Ltd., Thermofisher Scientific, QIAGEN, and Quest Diagnostics.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Scope of the Research Study

  • 2.1 Research Scope
  • 2.2 Key Questions Answered by the Research Study

3 Research Methodology

  • 3.1 Primary Data Sources
  • 3.2 Secondary Data Sources
  • 3.3 Market Estimation Model
  • 3.4 Selection Criteria for Company Profiles

4 Market Overview

  • 4.1 Introduction
  • 4.2 Evolution of Precision Medicine for Cancer Management and Treatment
  • 4.3 Applications of Precision Medicine in Oncology
    • 4.3.1 Identifying Genetic Mutations and Risks of Cancer Through Precision Diagnostics
    • 4.3.2 Promising Technological Developments Supporting Precision Oncology
      • 4.3.2.1 Low-Throughput Genomic Sequencing to High-Throughput Genomic Sequencing
      • 4.3.2.2 Multicell Hybrid Detection to Single-Cell Precision Detection
      • 4.3.2.3 Advancing Applications of ctDNA Detection Technology
      • 4.3.2.4 CRISPR/Cas Technology

5 Impact of COVID-19 Pandemic on Global Oncology Precision Medicine Market

  • 5.1 Disruption of Oncology Precision Medicine Due to COVID-19
  • 5.2 COVID-19 Affecting Supply Chain of Oncology Precision Medicine-Based Therapies
  • 5.3 Interruption in Research and Clinical Development and Commercial Operation
    • 5.3.1 Research and Clinical Development
    • 5.3.2 Commercial Operation and Access
  • 5.4 Navigating Crisis Recovery and Looking to the Future

6 Global Oncology Precision Medicine Market: Industry Analysis

  • 6.1 Legal and Regulatory Framework and Requirements
    • 6.1.1 North America
      • 6.1.1.1 Regulatory Requirements in U.S.
    • 6.1.2 Europe
    • 6.1.3 Asia-Pacific
  • 6.2 Legal Requirements and Framework by the MHLW
  • 6.3 Patent Landscape

7 Global Oncology Precision Medicine Market: Market Dynamics

  • 7.1 Overview
  • 7.2 Market Driving Factors
    • 7.2.1 Increasing Incidences of Cancer
    • 7.2.2 Decreasing Trial and Error-Based Drug Prescription Through Pharmacogenomics
    • 7.2.3 Increasing Usage of Predictive Biomarker for Diagnostics
    • 7.2.4 Rapid Technological Advancements
    • 7.2.5 Decreasing Cost of Genomic Sequencing
  • 7.3 Market Restraining Factors
    • 7.3.1 Large Scale Data Integration, Analysis and Establishment of Secure Data Libraries
    • 7.3.2 Inadequate Reimbursement Scenario for Precision Medicine
    • 7.3.3 Regulatory Barriers in the Advancement of Precision Medicine
    • 7.3.4 Lack of Expertise, Education, and Awareness for Precision Medicine Implementation
  • 7.4 Market Opportunities
    • 7.4.1 Unprecedented Improvements in Disease Modelling via In Silico, In Vitro, and In Vivo Methods
    • 7.4.2 Expansion into the Emerging Markets

8 Global Oncology Precision Medicine Market: Competitive Landscape

  • 8.1 Key Strategies and Developments
    • 8.1.1 Product Offerings
    • 8.1.2 Synergistic Activities
    • 8.1.3 Regulatory and Legal
    • 8.1.4 Mergers and Acquisitions
    • 8.1.5 Business Expansions and Funding
  • 8.2 Market Share Analysis
  • 8.3 Growth-Share Analysis (by Company), 2019

9 Global Oncology Precision Medicine Market (by Application), $Million, 2019-2030

  • 9.1 Overview
    • 9.1.1 Breast Cancer
    • 9.1.2 Lung Cancer
    • 9.1.3 Colorectal Cancer
    • 9.1.4 Prostate Cancer
    • 9.1.5 Cervical Cancer
    • 9.1.6 Other Cancer

10 Global Oncology Precision Medicine Market (by Ecosystem), $Million, 2019-2030

  • 10.1 Overview
  • 10.2 Applied Sciences
    • 10.2.1 Genomics
    • 10.2.2 Global Oncology Precision Medicine Genomics Market (by Technology)
      • 10.2.2.1 Polymerase Chain Reaction (PCR)
      • 10.2.2.2 Precision Medicine Next-Generation Sequencing (PM NGS)
      • 10.2.2.3 Genome Editing
      • 10.2.2.4 Other Technologies
    • 10.2.3 Pharmacogenomics
    • 10.2.4 Other Applied Sciences
  • 10.3 Precision Diagnostics
    • 10.3.1 Molecular Diagnostics (MDx)
    • 10.3.2 Medical Imaging
  • 10.4 Digital Health and Information Technology
    • 10.4.1 Clinical Decision Support Systems (CDSS)
    • 10.4.2 Big Data Analytics
    • 10.4.3 IT Infrastructure
    • 10.4.4 Genomics Informatics
    • 10.4.5 In-Silico Informatics
    • 10.4.6 Mobile Health
  • 10.5 Precision Therapeutics
    • 10.5.1 Clinical Trials
    • 10.5.2 Cell Therapy
    • 10.5.3 Drug Discovery and Research
    • 10.5.4 Gene Therapy

11 Global Oncology Precision Medicine Market (by Region), $Million, 2019-2030

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Europe Oncology Precision Medicine Market Dynamics
    • 11.3.2 Germany
    • 11.3.3 France
    • 11.3.4 Italy
    • 11.3.5 U.K.
    • 11.3.6 Spain
    • 11.3.7 Rest-of-Europe
  • 11.4 Asia-Pacific (APAC)
    • 11.4.1 Asia-Pacific Oncology Precision Medicine Market Dynamics
      • 11.4.1.1 China
      • 11.4.1.2 Japan
      • 11.4.1.3 Australia
      • 11.4.1.4 India
      • 11.4.1.5 Rest-of-Asia-Pacific
  • 11.5 Latin America
      • 11.5.1.1 Brazil
      • 11.5.1.2 Mexico
      • 11.5.1.3 Rest-of-LATAM
  • 11.6 Rest-of-the-World

12 Company Profiles

  • 12.1 Abbott Laboratories
    • 12.1.1 Company Overview
    • 12.1.2 Role of Abbott Laboratories in Global Oncology Precision Medicine Market
    • 12.1.3 Financials
    • 12.1.4 SWOT Analysis
  • 12.2 Agilent Technologies, Inc.
    • 12.2.1 Company Overview
    • 12.2.2 Role of Agilent Technologies, Inc. in Global Oncology Precision Medicine Market
    • 12.2.3 Financials
    • 12.2.4 SWOT Analysis
  • 12.3 Almac Group Ltd.
    • 12.3.1 Company Overview
    • 12.3.2 Role of Almac Group Ltd. in Global Oncology Precision Medicine Market
    • 12.3.3 SWOT Analysis
  • 12.4 ANGLE plc
    • 12.4.1 Company Overview
    • 12.4.2 Role of ANGLE plc in the Global Oncology Precision Medicine Market
    • 12.4.3 Financials
    • 12.4.4 Key Insights About Financial Health of the Company
    • 12.4.5 SWOT Analysis
  • 12.5 ASURAGEN INC.
    • 12.5.1 Company Overview
    • 12.5.2 Role of ASURAGEN Inc. in Global Oncology Precision Medicine Market
    • 12.5.3 SWOT Analysis
  • 12.6 BGI Group
    • 12.6.1 Company Overview
    • 12.6.2 Role of BGI Group in Global Oncology Precision Medicine Market
    • 12.6.3 SWOT Analysis
  • 12.7 Bio-Rad Laboratories, Inc.
    • 12.7.1 Company Overview
    • 12.7.2 Role of Bio-Rad Laboratories, Inc.in Global Oncology Precision Medicine Market
    • 12.7.3 Financials
    • 12.7.4 SWOT Analysis
  • 12.8 bioMerieux S.A.
    • 12.8.1 Company Overview
    • 12.8.2 Role of bioMerieux SA. in Global Oncology Precision Medicine Market
    • 12.8.3 Financials
    • 12.8.4 SWOT Analysis
  • 12.9 Bristol-Myers Squibb Company
    • 12.9.1 Company Overview
    • 12.9.2 Role of Bristol-Myers Squibb Company in Global Oncology Precision Medicine Market
    • 12.9.3 Financials
    • 12.9.4 SWOT Analysis
  • 12.1 F. Hoffmann-La Roche Ltd
    • 12.10.1 Company Overview
    • 12.10.2 Role of F. Hoffman-LA Roche Ltd in Global Oncology Precision Medicine Market
    • 12.10.3 Financials
    • 12.10.4 SWOT Analysis
  • 12.11 Gilead Sciences, Inc.
    • 12.11.1 Company Overview
    • 12.11.2 Role of Gilead Sciences, Inc. in Global Oncology Precision Medicine Market
    • 12.11.3 Financials
    • 12.11.4 SWOT Analysis
  • 12.12 Illumina, Inc.
    • 12.12.1 Company Overview
    • 12.12.2 Role of Illumina, Inc. in Global Oncology Precision Medicine Market
    • 12.12.3 Financials
    • 12.12.4 SWOT Analysis
  • 12.13 Konica Minolta, Inc.
    • 12.13.1 Company Overview
    • 12.13.2 Role of Konica Minolta, Inc. in Global Oncology Precision Medicine Market
    • 12.13.3 Financials
    • 12.13.4 SWOT Analysis
  • 12.14 Laboratory Corporation of America Holdings
    • 12.14.1 Company Overview
    • 12.14.2 Role of Laboratory Corporation of America Holdings in Global Oncology Precision Medicine Market
    • 12.14.3 Financials
    • 12.14.4 SWOT Analysis
  • 12.15 MDx Health, Inc.
    • 12.15.1 Company Overview
    • 12.15.2 Role of MDx Health, Inc. in the Global Precision Medicine Market
    • 12.15.3 Financials
    • 12.15.4 SWOT Analysis
  • 12.16 Myriad Genetics, Inc
    • 12.16.1 Company Overview
    • 12.16.2 Role of Myriad Genetics, Inc. in the Global Oncology Precision Medicine Market
    • 12.16.3 Financials
    • 12.16.4 Key Insights About Financial Health of the Company
    • 12.16.5 SWOT Analysis
  • 12.17 Novartis AG
    • 12.17.1 Company overview
    • 12.17.2 Role of Novartis AG in the Global Oncology Precision Medicine Market
    • 12.17.3 Financials
    • 12.17.4 Key Insights About Financial Health of the Company
    • 12.17.5 SWOT Analysis
  • 12.18 OPKO Health, Inc.
    • 12.18.1 Company Overview
    • 12.18.2 Role of OPKO Health, Inc. in Global Oncology Precision Medicine Market
    • 12.18.3 Financials
    • 12.18.4 SWOT Analysis
  • 12.19 Pacific Biosciences of California, Inc.
    • 12.19.1 Company Overview
    • 12.19.2 Role of Pacific Biosciences of California, Inc. in the Global Oncology Precision Medicine Market
    • 12.19.3 Financials
    • 12.19.4 Key Insights About Financial Health of the Company
    • 12.19.5 SWOT Analysis
  • 12.2 Quest Diagnostics
    • 12.20.1 Company Overview
    • 12.20.2 Role of Quest Diagnostics in Global Oncology Precision Medicine Market
    • 12.20.3 Financials
    • 12.20.4 SWOT Analysis
  • 12.21 QIAGEN N.V.*
    • 12.21.1 Company Overview
    • 12.21.2 Role of QIAGEN N.V. in Global Oncology Precision Medicine Market
    • 12.21.3 Financials
    • 12.21.4 SWOT Analysis
  • 12.22 Thermo Fisher Scientific Inc.
    • 12.22.1 Company Overview
    • 12.22.2 Role of Thermo Fisher Scientific Inc. in Global Oncology Precision Medicine Market
    • 12.22.3 Financials
    • 12.22.4 SWOT Analysis

List of Tables

  • Table 9.1: Estimated New Cancer Cases and Deaths,United States, 2020
  • Table 10.1: List of Few FDA Approved Pharmacogenomics Biomarkers in Drug Labelling

List of Figures

  • Figure 1: Overall Deaths due to Key Cancer Causes, in Millions, (2012-2019)
  • Figure 2: Global Oncology Precision Medicine Market, 2019-2030
  • Figure 3: Market Drivers, Opportunities, and Restraints
  • Figure 4: Share of Key Developments and Strategies, January 2016-November 2020
  • Figure 5: Growth-Share Matrix for Global Oncology Precision Medicine Market (by Company), 2019
  • Figure 6: Global Oncology Precision Medicine Applications Market Share (Application Type), 2019-2030
  • Figure 7: Global Oncology Precision Medicine Market (by Region)
  • Figure 2.1: Global Oncology Precision Medicine Market Segmentation
  • Figure 3.1: Global Oncology Precision Medicine Market Research Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Share of Total Number of Companies Profiled
  • Figure 4.1: Global Oncology Precision Medicine Market, 2019-2030
  • Figure 4.2: Evolution of Precision Medicine Technology
  • Figure 4.3: Molecular Diagnostics in Oncology
  • Figure 5.1: Number of Cancer Cases Diagnosed in the Netherlands (January 3, 2020, to April 12, 2020)
  • Figure 5.2: Pre-COVID-19 and Post-COVID-19 Scenario of Global Oncology Precision Medicine Market, 2017-2025
  • Figure 5.3: Areas of Disruption in Clinical Development
  • Figure 5.4: Measure to Navigate Crisis Recovery
  • Figure 6.1: FDA Guidelines for CDx Approval
  • Figure 6.2: Share of Patents Assigned (2015-2019)
  • Figure 6.3: Total Number of Patents Assigned to Key Technologies, 2016-2018
  • Figure 7.1: Impact Analysis of Market Dynamics
  • Figure 7.2: Rising Incidences of Cancer (2015 and 2018)
  • Figure 7.3: Estimated Cancer Incidences (Region-Wise), 2018 and 2040
  • Figure 7.4: Variable Outcomes of Pharmacologically Active Oncology Drugs and Prodrugs
  • Figure 7.5: Role of Biomarkers in Different Stages of Cancer
  • Figure 7.6: Significance of Biomarker on Treatment Monitoring
  • Figure 8.1: Share of Key Developments and Strategies, January 2016-November 2020
  • Figure 8.2: Share of Product Offerings, January 2016-August 2020
  • Figure 8.3: Share of Synergistic Activities, January 2016-August 2020
  • Figure 8.4: Share of Regulatory and Legal, January 2016-August 2020
  • Figure 8.5: Share of Mergers and Acquisitions, January 2016-August 2020
  • Figure 8.6: Share of Mergers and Acquisitions, January 2016-August 2020
  • Figure 8.7: Market Share Analysis: Global Oncology Precision Medicine Market, 2019
  • Figure 8.8: Growth-Share Matrix for Global Oncology Precision Medicine Market (by Company), 2019
  • Figure 9.1: Global Oncology Precision Medicine Market Share (by Application Type), 2019-2030
  • Figure 9.2: Global Oncology Precision Medicine Market (by Breast Cancer), 2019-2030
  • Figure 9.3: Global Oncology Precision Medicine Market (by Lung Cancer), 2019-2030
  • Figure 9.4: Global Oncology Precision Medicine Market (by Colorectal Cancer), 2019-2030
  • Figure 9.5: Global Oncology Precision Medicine Market (by Prostate Cancer), 2019-2030
  • Figure 9.6: Global Oncology Precision Medicine Market (by Cervical Cancer), 2019-2030
  • Figure 9.7: Global Oncology Precision Medicine Market (by Other Cancer), 2019-2030
  • Figure 10.1: Global Oncology Precision Medicine Market (by Ecosystem)
  • Figure 10.2: Precision Medicine: The Ecosystem
  • Figure 10.3: Global Oncology Precision Medicine Market (by Applied Sciences)
  • Figure 10.4: Global Oncology Precision Medicine Market (by Applied Sciences), 2019-2030
  • Figure 10.5: Global Oncology Precision Medicine Applied Sciences Market Share (by Type), 2019-2030
  • Figure 10.6: Global Oncology Precision Medicine Genomics Market, 2019-2030
  • Figure 10.7: Global Oncology Precision Medicine Genomics Market Share (by Technology)
  • Figure 10.8: Global Oncology Precision Medicine PCR Market, 2019-2030
  • Figure 10.9: Global Oncology Precision Medicine NGS Market, 2019-2030
  • Figure 10.10: Global Oncology Precision Medicine Genome Editing Market, 2019-2030
  • Figure 10.11: Global Oncology Precision Medicine Other Technologies Market, 2019-2030
  • Figure 10.12: Global Oncology Precision Medicine Pharmacogenomics Market, 2019-2030
  • Figure 10.13: Global Oncology Precision Medicine Other Applied Sciences Market, 2019-2030
  • Figure 10.14: Global Oncology Precision Medicine Market (by Precision Diagnostics)
  • Figure 10.15: Global Oncology Precision Medicine Market (by Precision Diagnostics), 2019-2030
  • Figure 10.16: Global Oncology Precision Medicine Diagnostics Market Share (by Type), 2019-2030
  • Figure 10.17: Global Oncology Precision Medicine Molecular Diagnostics Market, 2019-2030
  • Figure 10.18: Global Oncology Precision Medicine Medical Imaging Market, 2019-2030
  • Figure 10.19: Global Oncology Precision Medicine Digital Health and Information Technology Market, 2019-2030
  • Figure 10.20: Global Oncology Precision Medicine Digital Health and Information Technology Market Share (by Type), 2019-2030
  • Figure 10.21: Global Oncology Precision Medicine CDSS Market, 2019-2030
  • Figure 10.22: Global Oncology Precision Medicine Big Data Analytics Market, 2019-2030
  • Figure 10.23: Global Oncology Precision Medicine IT Infrastructure Market, 2019-2030
  • Figure 10.24: Global Oncology Precision Medicine Genomics Informatics Market, 2019-2030
  • Figure 10.25: Global Oncology Precision Medicine In-Silico Informatics Market, 2019-2030
  • Figure 10.26: Global Oncology Precision Medicine Mobile Health Market, 2019-2030
  • Figure 10.27: Global Oncology Precision Medicine Therapeutics Market, 2019-2030
  • Figure 10.28: Global Oncology Precision Medicine Therapeutics Market Share (by Type), 2019-2030
  • Figure 10.29: Global Oncology Precision Medicine Clinical Trials Market, 2019-2030
  • Figure 10.30: Global Oncology Precision Medicine Cell Therapy Market, 2019-2030
  • Figure 10.31: Global Oncology Precision Medicine Drug Discovery and Research Market, 2019-2030
  • Figure 10.32: Types of Gene Therapy
  • Figure 10.33: Global Oncology Precision Medicine Gene Therapy Market, 2019-2030
  • Figure 11.1: Global Oncology Precision Medicine Market (by Region)
  • Figure 11.2: North America Global Oncology Precision Medicine Market, 2019-2030
  • Figure 11.3: North America: Market Dynamics
  • Figure 11.4: North America Global Oncology Precision Medicine Market (by Country), 2019-2030
  • Figure 11.5: U.S. Oncology Precision Medicine Market, 2019-2030
  • Figure 11.6: Canada Oncology Precision Medicine Market, 2019-2030
  • Figure 11.7: Europe Oncology Precision Medicine Market, 2019-2030
  • Figure 11.8: Europe: Market Dynamics
  • Figure 11.9: Europe Oncology Precision Medicine Market (by Country), 2019-2030
  • Figure 11.10: Germany Oncology Precision Medicine Market, 2019-2030
  • Figure 11.11: France Oncology Precision Medicine Market, 2019-2030
  • Figure 11.12: Italy Oncology Precision Medicine Market, 2019-2030
  • Figure 11.13: U.K. Oncology Precision Medicine Market, 2019-2030
  • Figure 11.14: Spain Oncology Precision Medicine Market, 2019-2030
  • Figure 11.15: Rest-of-Europe Oncology Precision Medicine Market, 2019-2030
  • Figure 11.16: Asia-Pacific Oncology Precision Medicine Market, 2019-2030
  • Figure 11.17: Asia-Pacific: Market Dynamics
  • Figure 11.18: Asia-Pacific Oncology Precision Medicine Market (by Country), 2019-2030
  • Figure 11.19: China Oncology Precision Medicine Market, 2019-2030
  • Figure 11.20: Japan Oncology Precision Medicine Market, 2019-2030
  • Figure 11.21: Australia Oncology Precision Medicine Market, 2019-2030
  • Figure 11.22: India Oncology Precision Medicine Market, 2019-2030
  • Figure 11.23: Rest-of-Asia-Pacific Oncology Precision Medicine Market, 2019-2030
  • Figure 11.24: Latin America Oncology Precision Medicine Market, 2019-2030
  • Figure 11.25: Latin America: Market Dynamics
  • Figure 11.26: Latin America Global Oncology Precision Medicine Market (by Country), 2019 and 2030
  • Figure 11.27: Brazil Oncology Precision Medicine Market, 2019-2030
  • Figure 11.28: Mexico Oncology Precision Medicine Market, 2019-2030
  • Figure 11.29: Rest-of-LATAM Oncology Precision Medicine Market, 2019-2030
  • Figure 11.30: Rest-of-the-World Oncology Precision Medicine Market, 2019-2030
  • Figure 12.1: Abbott Laboratories: Overall Product Offerings
  • Figure 12.2: Abbott Laboratories: Overall Financials, 2017-2019
  • Figure 12.3: Abbott Laboratories: Net Revenue (by Business Segment), 2017-2019
  • Figure 12.4: Abbott Laboratories: Net Revenue (by Region), 2017-2019
  • Figure 12.5: Abbott Laboratories: Research and Development Expense, 2017-2019
  • Figure 12.6: Abbott Laboratories: SWOT Analysis
  • Figure 12.7: Agilent Technologies, Inc.: Overall Product Offerings
  • Figure 12.8: Agilent Technologies, Inc.: Overall Financials, 2017-2019
  • Figure 12.9: Agilent Technologies, Inc.: Net Revenue (by Business Segment), 2017-2019
  • Figure 12.10: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.11: Agilent Technologies, Inc.: Research and Development Expense, 2017-2019
  • Figure 12.12: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 12.13: Almac Group Ltd.: Overall Product Offerings
  • Figure 12.14: Almac Group Ltd.: SWOT Analysis
  • Figure 12.15: ANGLE plc: Overall Financials, 2017-2019
  • Figure 12.16: ANGLE plc: Revenue (by Region), 2018-2019
  • Figure 12.17: ANGLE plc R&D Expenditure, 2017-2019
  • Figure 12.18: ANGLE plc: SWOT Analysis
  • Figure 12.19: ASURAGEN, INC.: Overall Product Offerings
  • Figure 12.20: ASURAGEN INC.: SWOT Analysis
  • Figure 12.21: BGI Group.: Overall Product Portfolio
  • Figure 12.22: BGI Group: SWOT Analysis
  • Figure 12.23: Bio-Rad Laboratories, Inc: Overall Product Offerings
  • Figure 12.24: Bio-Rad Laboratories, Inc: Overall Financials, 2017-2019
  • Figure 12.25: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2017-2019
  • Figure 12.26: Bio-Rad Laboratories, Inc: Revenue (by Region), 2017-2019
  • Figure 12.27: Bio-Rad Laboratories, Inc. R&D Expenditure, 2017-2019
  • Figure 12.28: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 12.29: bioMerieux S.A.: Overall Product Portfolio
  • Figure 12.30: bioMerieux S.A.: Overall Financials, 2017-2019
  • Figure 12.31: bioMerieux S.A.: Revenue (by Segment), 2017-2019
  • Figure 12.32: bioMerieux S.A.: Revenue (by Region), 2018 and 2019
  • Figure 12.33: bioMerieux S.A.: SWOT Analysis
  • Figure 12.34: Bristol-Myers Squibb Company: Overall Product Portfolio
  • Figure 12.35: Bristol-Myers Squibb Company: Overall Financials, 2017-2019
  • Figure 12.36: Bristol-Myers Squibb Company R&D Expenditure, 2017-2019
  • Figure 12.37: Bristol-Myers Squibb Company: SWOT Analysis
  • Figure 12.38: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 12.39: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
  • Figure 12.40: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
  • Figure 12.41: Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
  • Figure 12.42: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
  • Figure 12.43: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 12.44: Gilead Sciences, Inc.: Overall Product Portfolio
  • Figure 12.45: Gilead Sciences, Inc.: Overall Financials, 2017-2019
  • Figure 12.46: Gilead Sciences, Inc.: R&D Expenditure, 2017-2019
  • Figure 12.47: Gilead Science, Inc.: SWOT Analysis
  • Figure 12.48: Illumina, Inc.: Overall Product Portfolio
  • Figure 12.49: Illumina, Inc.: Overall Financials, 2017-2019
  • Figure 12.50: Illumina, Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.51: Illumina, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.52: Illumina, Inc.: R&D Expenditure, 2017-2019
  • Figure 12.53: Illumina, Inc.: SWOT Analysis
  • Figure 12.54: Konica Minolta, Inc.: Overall Product Portfolio
  • Figure 12.55: Konica Minolta, Inc.: Overall Financials, 2017-2019
  • Figure 12.56: Konica Minolta, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.57: Konica Minolta, Inc.: Research and Development Expense, 2017-2019
  • Figure 12.58: Konica Minolta, Inc.: SWOT Analysis
  • Figure 12.59: Laboratory Corporation of America Holdings.: Overall Product Portfolio
  • Figure 12.60: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
  • Figure 12.61: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
  • Figure 12.62: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
  • Figure 12.63: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 12.64: MDx Health, Inc.: Overall Financials, 2017--2019
  • Figure 12.65: MDx Health, Inc.: SWOT Analysis
  • Figure 12.66: Myriad Genetics, Inc.: Product Portfolio
  • Figure 12.67: Myriad Genetics, Inc.: Overall Financials, 2017-2019
  • Figure 12.68: Myriad Genetics, Inc.: Revenue (by Business Segment), 2017-2019
  • Figure 12.69: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
  • Figure 12.70: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 12.71: Novartis AG: Overall Product Portfolio
  • Figure 12.72: Novartis AG: Overall Financials, 2017-2019
  • Figure 12.73: Novartis AG Net Revenue (by Business Segment), 2017-2019
  • Figure 12.74: Novartis AG: Net Revenue (by Region), 2017-2019
  • Figure 12.75: Novartis AG: R& D Expense, 2017-2019
  • Figure 12.76: Novartis AG: SWOT Analysis
  • Figure 12.77: OPKO Health, Inc.: Overall Product Portfolio
  • Figure 12.78: OPKO Health, Inc.: Overall Financials, 2017-2019
  • Figure 12.79: OPKO Health, Inc: Net Revenue (by Business Segment), 2017-2019
  • Figure 12.80: OPKO Health, Inc.: Net Revenue (by Region), 2017-2019
  • Figure 12.81: OPKO Health, Inc.: Research and Development Expense, 2017-2019
  • Figure 12.82: OPKO Health, Inc.: SWOT Analysis
  • Figure 12.83: Pacific Biosciences of California, Inc.: Overall Product Portfolio
  • Figure 12.84: Pacific Biosciences of California, Inc.: Overall Financials, 2017-2019
  • Figure 12.85: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.86: Pacific Biosciences of California, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.87: Pacific Biosciences of California, Inc.: R&D Expenditure, 2017-2019
  • Figure 12.88: Pacific Biosciences of California, Inc.: SWOT Analysis
  • Figure 12.89: Quest Diagnostics Incorporated: Overall Product Offerings
  • Figure 12.90: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
  • Figure 12.91: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2017-2019
  • Figure 12.92: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 12.93: QIAGEN N.V.: Overall Product Portfolio
  • Figure 12.94: QIAGEN N.V.: Overall Financials, 2017-2019
  • Figure 12.95: QIAGEN N.V.: Revenue (by Segment), 2017-2019
  • Figure 12.96: QIAGEN N.V.: Revenue (by Region), 2017-2019
  • Figure 12.97: QIAGEN N.V.: R&D Expenditure, 2017-2019
  • Figure 12.98: QIAGEN N.V.: SWOT Analysis
  • Figure 12.99: Thermo Fisher Scientific Inc.: Overall Product Portfolio
  • Figure 12.100: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
  • Figure 12.101: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.102: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
  • Figure 12.103: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
  • Figure 12.104: Thermo Fisher Scientific Inc.: SWOT Analysis